{"id":4406,"date":"2025-03-31T18:12:07","date_gmt":"2025-03-31T18:12:07","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/thalidomide-txt\/"},"modified":"2025-03-31T18:12:07","modified_gmt":"2025-03-31T18:12:07","slug":"thalidomide-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/thalidomide-txt\/","title":{"rendered":"Thalidomide.txt"},"content":{"rendered":"

CLINICAL USE <\/H3> Untreated multiple myeloma in patients >65 or who are ineligible for high dose chemotherapy, in combination with either melphalan and prednisone, or cyclophosphamide and dexamethasone (Unlicensed indications): Erythema nodusum leprosum Lupus erythematosus, aphthous ulceration, stomatitis, graft-versus-host disease, AIDS-associated waste syndrome, rheumatoid arthritis and other acute inflammatory conditions

DOSE IN NORMAL RENAL FUNCTION <\/H3> 200 mg daily Unlicensed dose: 50\u2013800 mg daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 258.2 <\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 55\u201366 <\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <0.7 <\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp : 166 litres <\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp : 5\u20137\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Unlikely to be dialysed. Dose as in normal renal function <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Unlikely to be dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp : Not dialysed. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp: Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3> Potentially hazardous interactions with other drugs Thalidomide enhances the effects of barbiturates, alcohol, chlorpromazine and reserpine Use with caution with other drugs that can cause peripheral neuropathy

    ADMINISTRATION <\/H3>

    Reconstition<\/H4> \u2013

    Route <\/H4> Oral

    Rate of Administration <\/H4> \u2013

    Comments<\/H4> \u2013

    OTHER INFORMATION <\/H4> Major route of elimination is non-renal (i.e. by spontaneous non-enzymatic hydrolytic cleavage) therefore normal doses may be given in renal failure Has been used to treat uraemic pruritus in haemodialysis patients unresponsive to other therapy. (Silva SR. Thalidomide for the treatment of uraemic pruritus: a crossover randomised double-blind trial. Nephron. 1994; 67(3): 270\u20133.) Can cause unexplained hyperkalaemia. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia.
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Untreated multiple myeloma in patients >65 or who<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4406","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4406"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4406\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}